Arogya Aarohan app & other AI-driven tools are being tested for early detection of diseases as part of Rs 300-cr initiative ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

“I think some of the new treatments will probably move the needle a little bit more in terms of treating this indication.” Ip MS. Update on the current treatment of diabetic retinopath ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Not available at this time. 1515 Aquarena Springs Drive, Ste. 105, San Marcos ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Striking a balance between innovation and responsibility is imperative. By prioritizing transparency, adhering to robust ...

The FDA previously agreed that together, these studies could constitute two adequate and well-controlled trials to support a potential New Drug Application ... being evaluated for the treatment of wet ...